Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Li M, Durbin KR, Sweet SM, Tipton JD, Zheng Y, Kelleher NL
[1] If you are pregnant, planning pregnancy, or breastfeeding, discuss alternative diabetes management strategies with your healthcare team
Immunol Lett 205:915
Phase 2 data showed weight loss exceeding 24% at the highest dose, surpassing both semaglutide and tirzepatide
The arguments for and against employer and insurer coverage of GLP-1s for weight loss tend to be short-term pain versus long-term gain
(Conference abstract reporting NA-931s efficacy in DIO mice: ~26% weight reduction, improved lipids, no muscle loss or serious adverse effects) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference) (NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss | Obesity Conferences 2024 | Weight Management Conferences 2024 | Obesity Events 2024 | Weight Management Congress | Obesity Conference)
